Press Releases

WASHINGTON, Feb. 13, 2012 /PRNewswire/ -- Radio One, Inc. (NASDAQ: ROIAK; ROIA) will be holding a conference call for investors, analysts and other interested parties to discuss its results for the fiscal year 2011.

(Logo: http://photos.prnewswire.com/prnh/20090806/PH57529LOGO)

The conference call is scheduled for Thursday, March 15, 2012 at 10:00 a.m. EDT. To participate on this call, U.S. callers may dial toll-free 1-800-230-1059; international callers may dial direct (+1) 612-234-9959.

A replay of the conference call will be available from 12:30 p.m. EDT March 16, 2012 until 11:59 p.m. March 18, 2012. Callers may access the replay by calling 1-800-475-6701; international callers may dial direct (+1) 320-365-3844. The replay Access Code is 237163. Access to live audio and a replay of the conference call will also be available on Radio One's corporate website at www.radio-one.com. The replay will be made available on the website for seven days after the call.

Cautionary Information Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements represent management's current expectations and are based upon information available to the Company at the time of this press release. These forward-looking statements involve known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, that may cause the actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially are described in the Company's reports on Forms 10-K, 10-K/A, 10-Q/A and 10-Q and other filings with the SEC.  The Company does not undertake any duty to update any forward-looking statements.

Radio One, Inc. (http://www.radio-one.com/) is a diversified media company that primarily targets African-American and urban consumers. The Company is one of the nation's largest radio broadcasting companies, currently owning or operating 53 broadcast stations located in 15 urban markets in the United States. As a part of its core broadcasting business, Radio One operates syndicated programming including the Russ Parr Morning Show, the Yolanda Adams Morning Show, the Rickey Smiley Morning Show, CoCo Brother Live, CoCo Brother's "Spirit" program, Bishop T.D. Jakes' "Empowering Moments", the Reverend Al Sharpton Show, and the Warren Ballentine Show. The Company also owns a controlling interest in Reach Media, Inc. (http://www.blackamericaweb.com/), owner of the Tom Joyner Morning Show and other businesses associated with Tom Joyner. Beyond its core radio broadcasting business, Radio One owns Interactive One (http://www.interactiveone.com/), an online platform serving the African-American community through social content, news, information, and entertainment, which operates a number of branded sites, including News One, UrbanDaily, HelloBeautiful, Community Connect Inc. (http://www.communityconnect.com/), an online social networking company, which operates a number of branded websites, including BlackPlanet, MiGente, and Asian Avenue. In addition, the Company owns a controlling interest in TV One, LLC (http://www.tvoneonline.com/), a cable/satellite network programming primarily to African-Americans.

SOURCE Radio One

HOUSTON, Feb. 13, 2012 /PRNewswire/ -- The Slick 50® brand has been protecting engines for over 34 years, just as long as legendary NASCAR crew chief and FOX Sports broadcaster Larry McReynolds has been tuning and caring for performance and race cars. Today Slick 50® is proud to announce a multi-year partnership with McReynolds to serve as consultant, official spokesperson and representative for Slick 50® and their products as they embark on a new brand expansion and communication program targeted at today's all around performance-minded drivers.

To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/slick-50-to-partner-with-former-nascar-crew-chief-and-fox-sports-analyst-larry-mcreynolds-139225249.html

McReynolds, one of NASCAR's most successful and influential crew chiefs has made a name for himself on and off the race track. Over the course of McReynold's career, he has accumulated 23 NASCAR Sprint Cup series wins, highlighted by leading two of NASCAR's most iconic drivers, Davey Allison and Dale Earnhardt, to Daytona 500 victories. For the past eleven years he has been a part of the Emmy Award-winning NASCAR on FOX broadcast team with Mike Joy and three-time Sprint Cup series champion Darrell Waltrip. Offering keen insight into the complicated inner-workings of race teams', including pit crew details, car descriptions and particulars of the driver/crew chief relationship, McReynolds has been a key asset in the success of the FOX broadcast team.

"I have been around performance engines all of my life. I am familiar with Slick 50® and the great reputation their products have. I have studied the most recent testing and performance data, and I am really looking forward to our relationship and being a big part of their marketing strategy moving forward," Larry stated.

Like McReynolds, Slick 50® is a leader in their industry providing engine treatment products, which are chemically formulated to protect against heat and friction and further the life of the consumer's engine, transmission and fuel system. 

"I am really excited to have Larry join the Slick 50® team," said Rusty Waples, Group Brand Manager, ITW Global Brands. "His in-depth knowledge of racing engines and influence in racing circles will really help us in our product development program. Plus, he is a trusted source of information for enthusiasts and we are going to leverage this in our advertising, social media and grass roots marketing. Look for great things to come from Larry and the Slick 50® brand."

James Stone, General Manager, ITW Global Brands, adds, "We are honored Larry McReynolds, a legend in racing and expert in performance tuning, has elected to partner with Slick 50® to help share real performance benefits with enthusiasts who want to maximize performance and longevity of their vehicles."

McReynolds will return to the broadcast booth this weekend including Saturday night, February 18th for the "Budweiser Shootout" at Daytona.

Since 1978, motorists have relied on Slick 50's® superior technology to protect their vehicle's vital parts from friction & wear, so they can achieve the performance they crave today and down the road. From Engine Treatments to Fuel System Cleaners to Transmission Treatments, Slick 50® products are formulated with superior chemistry to ensure they clean, protect and optimize performance of critical systems.  For more information on our products, please visit www.slick50.com.

SOURCE Slick 50

PHILADELPHIA, Feb. 13, 2012 /PRNewswire/ -- Aberdeen Asia-Pacific Income Fund, Inc. (NYSE AMEX: FAX) (the "Fund"), a closed-end bond fund, announced today that it will pay a monthly distribution of US 3.5 cents per share on March 16, 2012 to all shareholders of record as of February 29, 2012.

The Board's policy is to provide investors with a stable monthly distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital. This policy is subject to regular review at the Board's quarterly meetings unless market conditions require an earlier evaluation. The next review is scheduled to take place in March 2012.

For the 12 months to January 31, 2012, the Fund has paid total distributions amounting to $0.42 per share.  The composition of distributions paid by the Fund since the beginning of the Fund's fiscal year, November 1, 2011, will be estimated through the payment date, and announced at the time of payment of the distribution.   

The Fund is managed by Aberdeen Asset Management Asia Limited, advised by Aberdeen Asset Management Limited and sub-advised by Aberdeen Asset Management Investment Services Limited. The Fund's shares trade on the NYSE AMEX under the symbol "FAX".

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's Plan.

Closed-end funds have a one-time initial public offering and then are subsequently traded on the secondary market through one of the stock exchanges. The investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund's portfolio. There is no assurance that a fund will achieve its investment objective. Past performance does not guarantee future results.    

If you wish to receive this information electronically, please contact InvestorRelations@aberdeen-asset.com

www.aberdeenfax.com

Aberdeen Asset Management Asia Limited and Aberdeen Asset Management Limited are registered investment advisers under the Investment Advisers Act of 1940.

SOURCE Aberdeen Asia-Pacific Income Fund, Inc.

Trade Press and Flash Report Subscribers

Farm Equipment Monthly Sales Flash -- United States

CHICAGO, Feb. 13, 2012 /PRNewswire/ -- Month Ending January 31, 2012:

SOURCE Association of Equipment Manufacturers

SAN JOSE, Calif., Feb. 13, 2012 /PRNewswire/ -- SI-BONE, Inc. (San Jose, California), a medical device company that is pioneering the use of a minimally invasive surgical (MIS) device to treat the sacroiliac (SI) joint announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for broad method claims related to the iFuse Implant System.  SI-BONE currently markets the iFuse in the United States and European Union under the iFuse name.

Of considerable significance for SI-BONE, was the breadth of the method claims.  These claims include placing an elongated device across a joint from one bone to another, using a guide wire to place the implant, using a device that is rectilinear in cross-section, and a device having an exterior surface to provide bony in-growth.  "Because the market for minimally invasive surgical treatment of the SI joint is potentially so significant, this allowance provides SI-BONE with a strong competitive barrier.  Additionally, the Company has three dependent claims that further claim square, rectangular, and triangular cross-sections," according to Scott Yerby, Ph.D., Chief Technology Officer, SI-BONE.

This allowance reinforces the strength of SI-BONE's position regarding proper diagnosis and treatment of degenerative sacroiliitis and sacroiliac disruption and further secures its dominant market position as the leader in the MIS treatment space for the SI joint.  Increasingly, there is growing acceptance by surgeons that the SI joint is a significant source of unresolved low back pain (LBP) that requires an accurate diagnosis. 

Jeff Dunn, CEO of SI-BONE, stated, "We are pleased that this allowance provides our company with additional support for our clinical and commercial efforts.  It is a major competitive advantage to have the position of iFuse reinforced as the definitive MIS therapy and market leader for LBP patients with degenerative sacroiliitis.  We continue to pursue and will achieve strong intellectual property claims and expand our portfolio related to iFuse technology.  As arguably the fastest growing spine or orthopedic company in the world that is truly dedicated to both appropriate diagnosis and treatment, we will accomplish our mission of helping SI joint patients worldwide." 

The Company further noted that it has filed several additional US and foreign patent application in the past year that are focused on minimally invasive surgical technique, implantable devices, and supporting instrumentation related to the iFuse technology.

SI-BONE received clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System. The CE mark for European commercialization was obtained in November 2010. The iFuse provides immediate post-operative stabilization and accomplishes the goal of traditional SI joint fusion through an MIS approach. Clinical publications have identified the SI joint as a pain generator for up to 22 percent of low back pain patients.  In addition, DePalma, Pain Medicine 2011, identified the SI joint as a pain generator in low back pain in 40 to 61% of post-lumbar fusion patients, so-called 'failed back surgery' patients.(1) Effective treatment of the SI joint is a significant unmet clinical need and, when conservative therapy fails, iFuse may provide an option.

In response to increasing awareness of SI joint disruption and degenerative sacroiliitis as debilitating symptom generators, SI-BONE, Inc. developed an innovative, patented implant to treat the SI joint. The company is also embarking on a prospective multicenter study to document acute and long-term clinical outcomes in patients who are proven to be refractory to prior therapies.

The iFuse Implant System is a commercially available device in the U.S. intended for treatment of conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The iFuse procedure uses a minimal incision for delivery and implantation of small, titanium implants.  The implants are coated with a porous plasma spray that acts as an interference surface, designed to help decrease implant motion.  These implants have substantial thickness and sophisticated metallurgy and are able to produce a much stronger construct than that of conventional pins or screws used to surgically fix boney structures. The SI-BONE implant technology has been used successfully in over 2,000 MIS SI joint cases to-date.

About SI-BONE, Inc.SI-BONE, Inc. (San Jose, California) is the leading sacroiliac joint medical device company dedicated to the development of tools and products for diagnosing and treating patients with low back issues related to SI joint pathology.  The company has developed, and is manufacturing and marketing, less invasive approaches using implants for the treatment of SI joint disorders.  SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices.

(1) DePalma, M. Etiology of chronic LBP patients having undergone lumbar fusion. Pain Medicine, 2011;12:732-39.

SOURCE SI-BONE, INC.